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In this study, several influenza NS1 mutants were examined for their growth ability in interferon (IFN)-deficient Vero cells treated with
human interferon alpha (IFN-a). Mutants with an intact RNA binding domain showed similar growth properties as the wild-type virus,
whereas viruses carrying an impaired RNA binding domain were dramatically attenuated. Relying on the ability of the first half of the NS1
protein to antagonize the IFN action, we established a rescue system for the NS gene based on the transfection of one plasmid expressing
recombinant NS vRNA and subsequent coinfection with an IFN sensitive helper virus followed by adding of human IFN-a as a selection
drug. Using this method, a recombinant influenza A virus expressing green fluorescence protein (GFP) from the NS1 reading frame was
rescued. To ensure the posttranslational cleavage of GFP from the N-terminal 125 amino acids (aa) of NS1 protein, a peptide sequence
comprising a caspase recognition site (CRS) was inserted upstream the GFP protein. Although a rather long sequence of 275 aa was inserted
into the NS1 reading frame, the rescued recombinant vector appeared to be genetically stable while passaging in Vero cells and was able to
replicate in PKR knockout mice.
D 2004 Elsevier Inc. All rights reserved.Keywords: Influenza virus; GFP; NS1 reading frame
Introduction for the effective replication of the virus in its host. First, byInfluenza A viruses belong to the family Orthomyxo-
viridae and contain a segmented RNA genome consisting of
eight genomic fragments of negative polarity. Reverse
genetic methods have provided an excellent tool for the
studies of influenza virus genetics and for the development
of new generations of influenza vaccines and vectors
(Enami et al., 1990; Fodor et al., 1999; Luytjes et al.,
1989; Neumann and Kawaoka, 1999). One of the exten-
sively used targets for genetic manipulation of influenza A
viruses is the nonstructural protein 1 (NS1). It consists of
approximately 230 amino acids (aa), is early and abundantly
synthesized in infection, accumulated in the nucleus and
later in the cytoplasm of the infected cells (Krug and Soeiro,
1975; Lamb and Krug, 2001). The NS1 protein has been
suggested to perform several important accessory functions0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(A. Egorov).the activity of its carboxy-terminal domain, the NS1 protein
is able to inhibit the host mRNA’s processing mechanisms
(Krug et al., 2003). Second, it facilitates the preferential
translation of viral mRNA by direct interaction with the
cellular translation initiation factor eIF4GI (Aragon et al.,
2000). Third, by binding to dsRNA and interaction with
putative cellular kinase(s), the NS1 protein is able to prevent
the activation of interferon (IFN)-inducible dsRNA-activat-
ed kinase (PKR) (Bergmann et al., 2000; Hatada et al.,
1999; Tan and Katze, 1998), 2V,5V-oligoadenylate synthetase
system, and cytokine transcription factors such as NF-nB or
IRF 3 and c-Jun/ATF2 (Smith et al., 2001; Talon et al.,
2000; Wang et al., 2000). As result, the NS1 protein inhibits
the expression of INF-a and INF-h genes, delays the
development of apoptosis in the infected cells, and prevents
the formation of the antiviral state in neighboring cells.
The function of the NS1 protein as an a/h IFN antagonist
was proven by the construction of several NS mutants
bearing C-terminal deletions that showed impaired growth
properties in IFN-competent cells such as MDCK, embry-
onated chicken eggs, or mouse lungs, but had no attenuation
effect in IFN-deficient hosts such as Vero cells (Egorov et
C. Kittel et al. / Virology 324 (2004) 67–7368al., 1998) or PKR knockout mice (Bergmann et al., 2000). It
was found that an influenza NS mutant coding for just the
first N-terminal 125 amino acids was only slightly attenu-
ated in IFN-competent systems, while mutants carrying
shorter versions, respectively, less than 80 aa of the NS1
protein, were dramatically attenuated in MDCK cells and
mice (Egorov et al., 1998; Garcia-Sastre, 2002).
As mentioned before, Vero cells are defective in IFN type
I production due to a spontaneous gene deletion (Desmyter
et al., 1968; Mosca and Pitha, 1986). However, these cells
are competent responders to the treatment with exogenous
human interferon (IFN) (Lambropoulos and Koliais, 1989;
Schlender et al., 2000). In this study, we tested the ability of
several influenza A NS deletion mutants to circumvent the
antiviral state of Vero cells treated with human interferon
alpha (IFN-a). We found that NS mutants encoding for the
N-terminal 125 aa of the NS1 protein, but not mutants like
delNS1, completely lacking the NS1 ORF, were fully
resistant to the interferon action and were replicating as
efficient as the wild-type virus in human IFN-a-treated
cells. This encouraged us to establish a reverse genetic
system in Vero cells in which influenza NS transfectants
could be obtained with the help of human IFN-a used as a
selection drug against an IFN-sensitive helper virus. The
high efficiency of this system allowed us to rescue a
genetically stable influenza virus expressing green fluores-
cence protein (GFP) from the NS1 reading frame.Results
Growth of influenza NS mutants in Vero cells treated with
human IFN-a
To determine the IFN sensitivity of NS mutants, Vero
cells were infected with the wild-type PR8 virus or three
different NS mutants containing either only 125 N-terminal
aa (NS1–125), lacking NS1 ORF (delNS1), or harboring a
40 aa deletion (NS1-del40-80) in the N-terminal part of the
molecule (Fig. 1). The infected cells were incubated in the 
  
 
Fig. 1. Schematic structure of the NS1 proteins and growth on Vero cells in the p
grown in the presence or absence of 30 U/ml human IFN-a in Vero cells were d
recombinant NS1-GFP protein, an artificial caspase recognition site containing the
the GFP sequence. Arrows are marking the position of the putative caspase cleavpresence or absence of 30 U/ml human IFN-a and the viral
titers were compared 36 h postinfection. We found that
mutants delNS1 and NS1-del40-80 containing an impaired
RNA binding–dimerization domain showed dramatic atten-
uation in growth under the pressure of IFN-a, whereas the
wild-type virus, as well as the NS1 - 125 mutant, containing
an intact RNA binding domain showed almost similar titers
when incubated in the presence or absence of IFN-a (Fig.
1). Thus, the first N-terminal 125 aa of the NS1 protein
could serve as a resistance factor responsible for the
antagonizing of IFN action.
Rescuing of GFP-expressing influenza NS vector
Vero cells were transfected with plasmids expressing
the components of the influenza RNP complex and the
plasmid pPol-NS-Casp-GFP-HDV encoding chimeric
vRNA in which GFP was cloned into the NS1 reading
frame (Fig. 1) after aa 125. In addition, an artificial
CRS (DIDGGETDG) was introduced between those two
proteins to provide posttranslational separation of the
molecules.
Transfected cells were infected with an IFN-sensitive
helper virus (delNS1), and the virus yield was harvested 48
h postinfection. This yield contained at least 102 PFU/ml
progeny of the ‘‘fluorescent virus’’ and 105 PFU/ml of the
helper virus, determined by limiting dilution assay in Vero
cells without IFN-a treatment. Two passages in Vero cells in
the presence of IFN-a were performed to enrich the popu-
lation of the transfectant virus, and a pure GFP expressing
plaque was isolated. Further two rounds of plaque purifica-
tion in Vero cells, in which plaques were routinely examined
for GFP expression, allowed us to isolate a pure clone of
GFP-expressing virus designated as A/PR8/NS1-125GFP
(NS1-GFP). This virus, when applied at MOI = 1, was able
to induce expression of GFP as early as 6 h postinfection in
Vero and MDCK cells with full manifestation 24 h postin-
fection (Fig. 2). By Western blot analysis, we confirmed that
insertion of the CRS permitted the posttranslational cleav-
age of GFP from the N-terminal part of the NS1 protein 
resence of human IFN-a. Titers of the influenza PR8 virus and NS mutants
etermined 36 h postinfection using a plaquing assay on Vero cells. For the
motif DIDGGETDG was inserted after amino acid 125 of NS1 followed by
age site.
Fig. 2. Viral growth and GFP expression. Vero (A) and MDCK (B) cells were infected with the NS1-GFP, NS1-125, or delNS1 virus at MOI = 0.1. At different
time points, supernatants were assayed for infectious virus particles in limited dilution assays on Vero cells. GFP expression was analyzed 24 h postinfection on
Vero (C) or MDCK (D) cells using confocal microscopy.
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(R&D Systems) to the medium anticipated the cleavage,
confirming that cleavage occurred due to host cells caspase
activity. Moreover, the omitting of cleavage by caspase
inhibitors provoked the generation of deletion mutants
manifesting in several additional bands seen in the Western
blot (specially lane 2, Fig. 3).Fig. 3. Cleavage of recombinant NS-GFP protein in infected cells. MDCK cells
absence (lane 1 and 4) of the universal caspase inhibitor Z-VAD-FMK. Twelve ho
with anti-NS1 mouse serum (lane 1 and 2) and followed by alkaline phosphatase s
assay.Growth capacity of NS-GFP expression vector
The recombinant NS1-GFP virus was capable of repli-
cating in Vero cells up to the titers of 106–107 PFU/ml and
was not significantly attenuated in MDCK (Fig. 3) or in
Vero cells treated with 30 U/ml IFN-a (Fig. 1). Neverthe-
less, the genetic stability of the virus was not equal in IFN-were infected with the NS1-GFP virus in the presence (lane 2 and 3) and
urs postinfection, cells were lysed, analyzed by Western blot, and detected
taining or anti-GFP rabbit serum (lane 3 and 4) using a chemoluminescence
Fig. 4. Viral growth in mouse lungs. PKR+/+ mice or PKR/ mice were
infected intranasally with 5  104 PFU/animal of the transfectant virus. On
day 2, mouse lungs were titrated using a limiting dilution assay on Vero
cells and shown as geometric mean titer.
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passages in MDCK were causing an appearance of NS-GFP
deletion mutants in high frequency accompanied by the loss
of GFP expression after several passages. Sequence data of
these mutants confirmed that parts of the GFP encoding
sequence were removed due to spontaneous gene deletion.
The originated deletions were very heterogeneous, ranging
from several nucleotides up to the removal of approximately
80% of the C terminal part of the GFP protein. However,
deletion occurred solely in the GFP and never in the NS1
encoding sequence.
Replication in mice
Virus NS1-GFP revealed a full attenuation in the wild-
type mice (C57BL/6) as compared to the NS125 mutant,
which reached a titer of 5  104 PFU/g in the lung tissues 2
days postinfection (Fig. 4). However, the infection of PKR
knockout (PKR/) mice, previously shown to support the
replication of the delNS1 virus, resulted in the replication of
the GFP expressing vector in lung tissues to 4  104 PFU/g,
detected 2 days postinfection. Furthermore, even after 2
days of replication in mouse lungs, the virus was still
expressing GFP when titrated in Vero cells.Discussion
The influenza virus is considered a potential vaccine
vector that could deliver various antigens into nasal tissues
inducing systemic and mucosal T- and B-cell immune
response (Ferko et al., 2001; Garcia-Sastre and Palese,
1995). One of the advantages of using the influenza virus
as viral vectors, in contrast to other systems such as
adenoviral vectors or retroviruses, is that it does not contain
a DNA intermediate and therefore is not able to integrateinto the host’s chromosomes. In addition, live influenza
virus vaccines have been developed and licensed for
humans and can be theoretically used for the expression
of additional antigens. The influenza NS1 protein has
several advantages as a target for engineering because it
has a nonstructural nature and therefore does not presum-
ably interfere with the structure of the virions, but is
synthesized in large quantities in infected cells. Several
groups have succeeded in introducing foreign protein
sequences such as CAT or HIV Nef into the NS1 reading
frame of influenza A virus. Furthermore, it has been shown
that influenza viruses expressing foreign epitopes from the
NS1 reading frame could elicit both humoral and cellular
immune responses (Ferko et al., 2001; Takasuka et al.,
2002). However, it still remains to be elucidated what could
be the maximal length of inserted foreign sequences that
influenza A NS1 protein can tolerate and where would the
optimal position be for introducing them. This requires
better understanding of the structure–functional organiza-
tion of the NS1 molecule.
One of the well-determined functions of the NS1 protein
is its ability to antagonize an a/h IFN-induced antiviral
response. The mechanisms by which the NS1 protein exerts
its function to evade the host antiviral response are not yet
fully understood. However, it is clear that in primary
infected cells, one of the main strategies of the influenza
virus is to inhibit IFNa/h signaling to the neighboring cells,
which can induce their antiviral state by stimulation of
transcription INF-stimulated response element (ISRE) pro-
moter containing genes (Stark et al., 1998). Among
hundreds of genes transcriptionally stimulated by interfer-
ons, several are involved in the inhibition of viral replica-
tion: the PKR, the 2V, 5V-oligoadenylate synthetases, and the
Mx protein (Garcia-Sastre, 2002). Many viruses have
evolved different mechanisms to counteract with interferon
response. In this report, we demonstrated that influenza
viruses carrying the wt NS gene or mutants encoding 125
N-terminal aa of NS1 protein can efficiently grow in Vero
cells treated with human IFN-a, whereas mutants with an
affected RNA binding domain are fully attenuated. In other
words, we have demonstrated that the influenza virus is able
to circumvent the antiviral state of the interferon-treated
cells most likely by the activity of the NS1 protein RNA
binding domain.
Using the 125 aa N-terminal half of the NS1 protein as a
drug resistance factor, we established a reverse genetic
system for the influenza NS gene that combines transfection
of Vero cells with a plasmid expressing recombinant NS
vRNA and infection with IFN-sensitive delNS1 helper virus
under IFN-a pressure. The delNS1 virus, after playing the
part of its helper function, was easily eliminated from the
viral population by treatment of Vero cells with human IFN-
a. This system appeared to be a powerful tool for the
obtaining of various influenza NS mutants (data not shown).
As a challenge for the efficacy of this method, we tried to
obtain an influenza virus expressing GFP from the NS1
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rescue NS transfectants with inserts of more than 275 aa
(e.g., GFP) using plasmid only transfection system were not
fruitful.
For the rescuing of the GFP expressing vector, we had to
enhance the efficiency of our rescue system by co-transfec-
tion of additional four plasmids expressing the proteins of
the viral polymerase complex (RNP), as described in
Pleschka et al. (1996). In addition, a new cleavage site
encoding a caspase recognition sequence was introduced to
provide posttranslational separation of the parts of the
recombinant NS1 molecule. The rescued NS1-GFP virus
was replicating to high titers and was genetically stable
while passaging in Vero cells, generating 100% fluorescent
plaques. At the same time, although the virus was growing
and expressing GFP in IFN competent cells, it was losing its
fluorescing activity due to the appearance of various dele-
tions within the GFP sequence. Therefore, it can be con-
cluded that although the virus had an intact N-terminal part
of the NS1 protein that was efficiently released from the
GFP molecule by caspase cleavage, the IFN antagonizing
function of NS1-GFP virus was still partially compromised.
Although the NS1-GFP virus was growing in IFN-compe-
tent cells, it was not able to replicate in wild-type C57/bl
mice, behaving quite similar as the delNS1 virus, which
completely lacks the NS1 ORF. In contrast, PKR knockout
mice were supporting the replication of NS1-GFP virus in
the lungs having a titer of more than 104 PFU/g of lung
tissues, as it was shown for delNS1 (Bergmann et al., 2000).
Moreover, even after 2 days of replication in mouse lungs,
the virus did not lose its capacity to express GFP.
The effect that influenza NS mutants carrying carboxy-
terminal deletions are replicating to high titers in tissue
culture but are significantly attenuated in wt mice was
previously described and studied (Wang et al., 2002). In fact,
several vectors that were constructed in our laboratory by
inserting foreign sequences into aa position 125 of NS1 were
replication-deficient in mice despite their capacity to grow in
IFN-a-treated Vero cells. Several reasons should be consid-
ered as an explanation of this attenuation effect in vivo. First,
the lack of the NS1 effector domain could already cause some
extent of attenuation and its function could be more important
in animals than in tissue culture. Second, recently, it has been
demonstrated that attenuated influenza NS1 mutants carrying
just 73 or 126 aa of the N-terminal part of NS1 could be
converted to a more virulent phenotype by elongation of the
NS1 with the sequences promoting dimerization (Wang et al.,
2002). In our case, the GFP insert could have some negative
influence on the formation of the NS1 dimers, making NS1
function to be less efficient and therefore promoting the
activation of PKR. Finally, it has to be elucidated what kind
of attenuation effect the inserted CRS may have by interact-
ing with various caspases in the infected cells. Our prelim-
inary results have indicated that the created CRS resulted in
the delay of nucleoaccumulation of the NS1 protein in
infected cells.In conclusion, we have demonstrated that the influenza
virus can be engineered in such a way that foreign sequences
that are even longer than the NS1 protein itself can be
expressed from the NS1 reading frame and that such viruses
could be successfully maintained and propagated to high
titers in Vero cells. In addition, the constructed GFP express-
ing viral vector could be used as a tool for the tracking of
influenza virus infection in knockout animals and for the fast
screening of antiviral drugs against influenza.Materials and methods
Viruses and cells
Vero and MDCK cell lines originate from the American
Type Culture Collection (ATCC). Vero cells were adapted to
and further cultivated in DMEM–Ham’s F12 (Biochrom
F4815) with 4 mM L-glutamine and protein-free supplement
(proprietary formulation, Polymun Scientific GmbH, Aus-
tria). MDCK cells were cultivated in DMEM–Ham’s F12
medium containing 2% heat-inactivated fetal calf serum
(FCS, HyClone SH30071) and 4 mM L-glutamine. Influenza
virus A/PR/8/34 (H1N1) (PR8) and NS mutants A/PR8/
delNS1 (delNS1), A/PR8/NS1-125 (NS1-125), and A/PR8/
NS1-del40-80 (NS1-del40-80) (Fig. 1) were obtained in
Vero cells by using the transfection protocol as described
in Egorov et al. (1998). All viruses were grown and titrated
in Vero cells at 37 jC.
Construction of plasmids
Viral RNA from influenza PR8 was extracted with
Ultraspec RNA purification reagent (Biotecx Laboratories),
reverse transcribed using M-MuLV reverse transcriptase
(MBI), and served as a template for subsequent amplifi-
cation of the NS gene by PCR. The NS sequence was
blunt end cloned between the PolI promoter and the
Hepatitis delta virus (HDV) genomic ribozyme and desig-
nated as pPolI-NS-HDV (Fodor et al., 1999; Neumann et
al., 1999; Pleschka et al., 1996; Poomputsa et al., 2003).
Oligonucleotides coding for the CRS (5V-ATTGATG-
GAGGTGAAACTGATGGG-3V and 5V-CCCATCAGTTT-
CACCTCCATCAAT-3V) were synthesized (Invitrogen),
annealed, and blunt end ligated into plasmid pPolI-NS-
HDV after nucleotide position 400 of NS and the resulting
plasmid was named pPol-NS125Casp-HDV. Insertion of
the GFP encoding sequence (Quantum’s SuperGlok GFP,
extracted from Vector pQBI25-fc1, Qbiogene) into plasmid
pPol-NS125Casp-HDV downstream the CRS resulted in
the plasmid pPol-NS-Casp-GFP-HDV. The expression
plasmids for PB1, PB2, PA, and NP influenza proteins
were obtained by cloning of the corresponding PR8 genes
into the Vector pTriEx-1 (Novagene) under the chicken
actin promoter and designated pTriEx-PB1, pTriEx-PB2,
pTriEx-PA, and pTriEx-NP, respectively.
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Ninety percent confluent Vero cells were transfected
with 1 Ag of each plasmid pPol-NS-Casp-GFP-HDV,
pTriEx-NP, pTriEx-PA, pTriEx-PB1, and pTriEx-PB2 us-
ing the Nucleofection technique (Amaxa), according to the
manufacturer’s instruction manual. Twenty-four hours lat-
er, cells were examined for GFP expression and infected
with delNS1 helper virus (MOI = 0.1). Eight hours
postinfection, 3 U of human IFN-a (NIBSC 1st Interna-
tional Standard 1999, human leukocyte derived, suspended
in RPMI media (Biochrom F1512) containing 10% heat-
inactivated fetal calf serum and 4 mM L-glutamine) per ml
culture medium was added and cells were incubated 48
h at 37 jC. The supernatant was passaged twice in Vero
cells in the presence of IFN-a at a concentration of 3 U/
ml and plaqued in Vero cells. Plaques containing the
correct NS1-GFP gene were identified by RT-PCR. Fol-
lowing two rounds of plaque purification, in which plaques
were routinely examined for GFP expression, a pure virus
could be isolated. This virus was designated as A/PR8/
NS1-125GFP (NS1-GFP), analyzed by RT-PCR, and the
correct sequence was confirmed by nucleotide sequence
analysis.
Viral replication in mouse lungs
Four- to 6-week-old C57BL/6 mice or PKR knockout
(PKR/) mice, which were derived from C57BL/6 mice by
the targeted deletion of PKR (Yang et al., 1995), were
infected intranasally (in) with 5  104 PFU/animal of the
virus under ether anesthesia. At day two, mice were sacri-
ficed and lungs aseptically removed. A 10% tissue extract in
PBS was prepared by grinding the tissue sample with a rotor
homogenizer. The suspension was centrifuged at 2000  g
for 5 min and the viral yield of the supernatants was
determined by limiting dilution assay in Vero cells.
Polyacrylamide gel electrophoresis and Western blot
analysis
SDS-PAGE of virus preparations was carried out using
Tris-Glycine 16% gels (Anamed). Western blotting was
performed by electrophoretic transfer of the proteins from
the gel to a polyvinyl difluoride membrane (Millipore) for 2
h at 400 mA. After overnight blocking in TPBS (PBS with
0.1% Tween 20) containing 3% of skim milk, the membrane
was incubated for 1 h with specific mouse anti-NS1-GST or
rabbit anti-GFP antisera (Clontech) and diluted 1:5000 in
TPBS buffer containing 1% of skim milk. After washing
with TPBS, the membrane was either incubated for 1 h with
anti-mouse alkaline phosphatase or anti-rabbit peroxidase-
labeled conjugate (Sigma) diluted 1:40000 in TPBS con-
taining 1% of skim milk. The blots were developed in
staining buffer (100 mM Tris–HCl, 100 mM NaCl, 5 mM
MgCl2, pH 9.5) with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate or by ECL plus Western Blot-
ting Detection system (Amersham) for chemoluminescence,
respectively.Acknowledgments
This work was financed by Polymun Scientific, Immun-
biologische Forschung GmbH, Vienna, and supported in
part by the ‘‘Fonds zur Fo¨rderung der wissenschaftlichen
Forschung’’, Austria (FWF), Project number P13715-B13.
We would like to thank Thomas Muster for providing us
with the PKR knockout mice.References
Aragon, T., de la Luna, S., Novoa, I., Carrasco, L., Ortin, J., Nieto, A.,
2000. Eukaryotic translation initiation factor 4GI is a cellular target for
NS1 protein, a translational activator of influenza virus. Mol. Cell. Biol.
20 (17), 6259–6268.
Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K.,
Palese, P., Muster, T., 2000. Influenza virus NS1 protein counteracts
PKR-mediated inhibition of replication. J. Virol., 74.
Desmyter, J., Melnick, J.L., Rawls, W.E., 1968. Defectiveness of interferon
production and of rubella virus interference in a line of African green
monkey kidney cells (Vero). J. Virol. 2 (10), 955–961.
Egorov, A., Brandt, S., Sereinig, S., Romanova, J., Ferko, B., Katinger, D.,
Grassauer, A., Alexandrova, G., Katinger, H., Muster, T., 1998. Trans-
fectant influenza A viruses with long deletions in the NS1 protein grow
efficiently in Vero cells. J. Virol. 72 (8), 6437–6441.
Enami, M., Luytjes, W., Krystal, M., Palese, P., 1990. Introduction of site-
specific mutations into the genome of influenza virus. Proc. Natl. Acad.
Sci. U.S.A. 87 (10), 3802–3805.
Ferko, B., Stasakova, J., Sereinig, S., Romanova, J., Katinger, D., Niebler,
B., Katinger, H., Egorov, A., 2001. Hyperattenuated recombinant influ-
enza A virus nonstructural-protein-encoding vectors induce human im-
munodeficiency virus type 1 Nef-specific systemic and mucosal
immune responses in mice. J. Virol. 75 (19), 8899–8908.
Fodor, E., Devenish, L., Engelhardt, O.G., Palese, P., Brownlee, G.G.,
Garcia-Sastre, A., 1999. Rescue of influenza A virus from recombinant
DNA. J. Virol. 73 (11), 9679–9682.
Garcia-Sastre, A., 2002. Mechanisms of inhibition of the host interferon
alpha/beta-mediated antiviral responses by viruses. Microb. Infect. 4
(6), 647–655.
Garcia-Sastre, A., Palese, P., 1995. Influenza virus vectors. Biologicals 23
(2), 171–178.
Hatada, E., Saito, S., Fukuda, R., 1999. Mutant influenza viruses with a
defective NS1 protein cannot block the activation of PKR in infected
cells. J. Virol. 73 (3), 2425–2433.
Krug, R.M., Soeiro, R., 1975. Studies on the intranuclear localization of
influenza virus-specific proteins. Virology 64 (2), 378–387.
Krug, R.M., Yuan, W., Noah, D.L., Latham, A.G., 2003. Intracellular war-
fare between human influenza viruses and human cells: the roles of the
viral NS1 protein. Virology 309 (2), 181–189.
Lamb, R.A., Krug, R.M., 2001. Orthomyxoviridae: the viruses and their
replication. Fields Virology, 4th ed. Lippincott Williams & Wilkins,
Philadelphia, pp. 1487–1532.
Lambropoulos, A.F., Koliais, S.I., 1989. Induction of 2V,5V oligo(A) syn-
thetase in Vero cells. Microbiologica 12 (2), 105–111.
Luytjes, W., Krystal, M., Enami, M., Pavin, J.D., Palese, P., 1989. Ampli-
fication, expression, and packaging of foreign gene by influenza virus.
Cell 59 (6), 1107–1113.
C. Kittel et al. / Virology 324 (2004) 67–73 73Mosca, J.D., Pitha, P.M., 1986. Transcriptional and posttranscriptional reg-
ulation of exogenous human beta interferon gene in simian cells defec-
tive in interferon synthesis. Mol. Cell. Biol. 6 (6), 2279–2283.
Neumann, G., Kawaoka, Y., 1999. Genetic engineering of influenza and
other negative-strand RNA viruses containing segmented genomes.
Adv. Virus Res. 53, 265–300.
Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P.,
Hughes, M., Perez, D.R., Donis, R., Hoffmann, E., Hobom, G.,
Kawaoka, Y., 1999. Generation of influenza A viruses entirely from
cloned cDNAs. Proc. Natl. Acad. Sci. U.S.A. 96 (16), 9345–9350.
Pleschka, S., Jaskunas, R., Engelhardt, O.G., Zurcher, T., Palese, P., Garcia-
Sastre, A., 1996. A plasmid-based reverse genetics system for influenza
A virus. J. Virol. 70 (6), 4188–4192.
Poomputsa, K., Kittel, C., Egorov, A., Ernst, W., Grabherr, R., 2003. Gen-
eration of recombinant influenza virus using baculovirus delivery vec-
tor. J. Virol. Methods 110 (1), 111–114.
Schlender, J., Bossert, B., Buchholz, U., Conzelmann, K.K., 2000. Bovine
respiratory syncytial virus nonstructural proteins NS1 and NS2 cooper-
atively antagonize alpha/beta interferon-induced antiviral response. J.
Virol. 74 (18), 8234–8242.
Smith, E.J., Marie, I., Prakash, A., Garcia-Sastre, A., Levy, D.E., 2001.
IRF3 and IRF7 phosphorylation in virus-infected cells does not require
double-stranded RNA-dependent protein kinase R or Ikappa B kinase
but is blocked by vaccinia virus E3L protein. J. Biol. Chem. 276 (12),
8951–8957.
Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., Schreiber,R.D., 1998. How cells respond to interferons. Annu. Rev. Biochem.
67, 227–264.
Takasuka, N., Enami, M., Itamura, S., Takemori, T., 2002. Intranasal inoc-
ulation of a recombinant influenza virus containing exogenous nucleo-
tides in the NS segment induces mucosal immune response against the
exogenous gene product in mice. Vaccine 20 (11–12), 1579–1585.
Talon, J., Horvath, C.M., Polley, R., Basler, C.F., Muster, T., Palese, P.,
Garcia-Sastre, A., 2000. Activation of interferon regulatory factor 3
is inhibited by the influenza A virus NS1 protein. J. Virol. 74 (17),
7989–7996.
Tan, S.L., Katze, M.G., 1998. Biochemical and genetic evidence for com-
plex formation between the influenza A virus NS1 protein and the
interferon-induced PKR protein kinase. J. Interferon Cytokine Res. 18
(9), 757–766.
Wang, X., Li, M., Zheng, H., Muster, T., Palese, P., Beg, A.A., Garcia-
Sastre, A., 2000. Influenza A virus NS1 protein prevents activation of
NF-kappaB and induction of alpha/beta interferon. J. Virol. 74 (24),
11566–11573.
Wang, X., Basler, C.F., Williams, B.R., Silverman, R.H., Palese, P., Garcia-
Sastre, A., 2002. Functional replacement of the carboxy-terminal two-
thirds of the influenza A virus NS1 protein with short heterologous
dimerization domains. J. Virol. 76 (24), 12951–12962.
Yang, Y.L., Reis, L.F., Pavlovic, J., Aguzzi, A., Schafer, R., Kumar, A.,
Williams, B.R., Aguet, M., Weissmann, C., 1995. Deficient signaling in
mice devoid of double-stranded RNA-dependent protein kinase. EMBO
J. 14 (24), 6095–6106.
